Drug Study (Mucosulvan, Verorab, Tetanus Toxoid)

"Tetanus Toxoid"

GENERIC NAME: Anti-tetanus serum

BRAND NAME: Tetanus Toxoid
GENERAL CLASSIFICATION: EPI vaccine, Anti-tetanus

INDICATION:
 Tetanus Toxoid is indicated for booster injection only for persons 7 yrs of age and older
against tetanus.
 Primary immunization schedule for children under 7 yrs of age should consist of five doses of
vaccine containing tetanus toxoid.
 Tetanus Toxoid is not to be used for treatment of tetanus infection.
 As with any vaccine, vaccination with tetanus toxoid may not protect 100% of susceptible
individuals.
DOSAGES:
 After the initial immunization series is completed, a booster dose of 0.5mL of tetanus toxoid
should be given intramuscularly every 10 yrs to maintain adequate immunity.
SIDE EFFECT/ ADVERSE REACTION:
o Body System as a whole:
Redness, warmth, edema, induration with or without tenderness as well as urticaria, and rash.
Malaise, transient fever, pain, hypotension, nausea, and arthralgia
NURSING CONSIDERATION:
 Shake well the vial before withdrawing each dose
 Special care should be taken to ensure that the injection does not enter the blood vessel
 For Nursing Mothers:
Tetanus Toxoid does not affect the safety of mothers who are breastfeeding or their infants.
Breastfeeding does not adversely affect immune response and is not a contraindication for
vaccination
 For Pediatric Use:
Safety and effectiveness of tetanus toxoid in infants below the age of 6 weeks has not been
established. However, this vaccine is not indicated for children under 7 yrs of age.
 For Geriatric Use:
Tetanus Toxoid should only be used in geriatric patients known to have received a primary series
of tetanus-containing vaccine, since many such as persons have no prior immunity.